Skip to main content
main-content

Zeitschrift

Targeted Oncology

Targeted Oncology OnlineFirst articles

14.02.2019 | Adis Drug Evaluation

Cabozantinib: A Review in Advanced Hepatocellular Carcinoma

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) with roles in cancer pathogenesis. This review focuses on data relevant to the use of cabozantinib tablets (Cabometyx®) in the treatment of hepatocellular carcinoma (HCC) in …

11.02.2019 | Original Research Article Open Access

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Focal adhesion kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), is a non-receptor cytokine tyrosine kinase that comprises a structural component of focal adhesions. These focal adhesions are protein complexes containing cell surface …

11.02.2019 | Original Research Article Open Access

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Cellular interactions with the extracellular matrix play a pivotal role in tumor initiation, progression, and metastasis [ 1 ]. Focal adhesion kinase [FAK; also known as protein tyrosine kinase 2 (PTK2)] is a widely expressed, nonreceptor …

06.02.2019 | Original Research Article Open Access

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

Focal adhesion kinase (FAK)/protein tyrosine kinase 2 is a ubiquitous, non-receptor, cytoplasmic tyrosine kinase that localizes to areas of focal adhesion where the plasma membrane makes contact with the extracellular matrix [ 1 – 4 ]. FAK is a key …

29.01.2019 | Review Article

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

Bladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including …

Aktuelle Ausgaben

Weitere Informationen


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise